LCTX Logo

Lineage Cell Therapeutics Inc (LCTX) Stock Forecast & Price Prediction

Live LCTX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$0.69

+0.00 (0.00%)

12 Month Price Forecast For LCTX

$0.69
Current Price
$158.47M
Market Cap
7 Ratings
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to LCTX Price Forecasts

+1,204.3%
To High Target of $9.00
+479.7%
To Median Target of $4.00
+189.9%
To Low Target of $2.00

LCTX Price Momentum

+3.0%
1 Week Change
+19.0%
1 Month Change
-38.9%
1 Year Change
+38.0%
Year-to-Date Change
-57.1%
From 52W High of $1.61
+43.8%
From 52W Low of $0.48

๐Ÿค” Considering Lineage (LCTX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 3:49 AM UTC

LCTX Analyst Ratings & Price Targets

Based on our analysis of 8 Wall Street analysts, LCTX has a bullish consensus with a median price target of $4.00 (ranging from $2.00 to $9.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $0.69, the median forecast implies a 479.7% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,204.3% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 189.9% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

LCTX Analyst Consensus

6
Buy
1
Hold
0
Sell

LCTX Price Target Range

Low
$2.00
Average
$4.00
High
$9.00
Current: $0.69

Latest LCTX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for LCTX.

Date Firm Analyst Rating Change Price Target
Feb 11, 2025 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $9.00
Feb 11, 2025 D. Boral Capital Jason Kolbert Buy Maintains $2.00
Jan 31, 2025 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $9.00
Jan 10, 2025 Maxim Group Michael Okunewitch Buy Maintains $3.00
Jan 3, 2025 D. Boral Capital Jason Kolbert Buy Maintains $2.00
Dec 4, 2024 HC Wainwright & Co. Joseph Pantginis Buy Maintains $9.00
Nov 20, 2024 D. Boral Capital Jason Kolbert Buy Maintains $2.00
Nov 18, 2024 D. Boral Capital Jason Kolbert Buy Initiates $3.00
Aug 20, 2024 Craig-Hallum Albert Lowe Buy Initiates $4.00
May 6, 2024 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Mar 8, 2024 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Feb 13, 2024 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Feb 5, 2024 Cantor Fitzgerald Kristen Kluska Overweight Reiterates $6.00
Aug 11, 2023 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Jul 25, 2023 Cantor Fitzgerald Overweight Reiterates $0.00
Jul 24, 2023 HC Wainwright & Co. Buy Reiterates $0.00
May 12, 2023 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Apr 26, 2023 HC Wainwright & Co. Joseph Pantginis Buy Reiterates $7.00
Mar 10, 2023 HC Wainwright & Co. Buy Reiterates $7.00
Nov 2, 2022 Baird Jack Allen Outperform Initiates $5.00

Stocks Similar to Lineage Cell Therapeutics Inc

The following stocks are similar to Lineage based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Lineage Cell Therapeutics Inc (LCTX) Financial Data

Lineage Cell Therapeutics Inc has a market capitalization of $158.47M with a P/E ratio of -5.8x. The company generates $6.19M in trailing twelve-month revenue with a 92.5% profit margin.

Revenue growth is -56.3% quarter-over-quarter, while maintaining an operating margin of -416.7% and return on equity of -35.0%.

Valuation Metrics

Market Cap $158.47M
Enterprise Value $130.15M
P/E Ratio -5.8x
PEG Ratio -4.6x
Price/Sales 25.6x

Growth & Margins

Revenue Growth (YoY) -56.3%
Gross Margin +99.0%
Operating Margin -416.7%
Net Margin +92.5%
EPS Growth +203.3%

Financial Health

Cash/Price Ratio +29.6%
Current Ratio 2.6x
Debt/Equity 4.4x
ROE -35.0%
ROA -12.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Lineage Cell Therapeutics Inc logo

Lineage Cell Therapeutics Inc (LCTX) Company Overview

About Lineage Cell Therapeutics Inc

What They Do

Develops innovative cell therapies for medical needs.

Business Model

The company operates as a clinical-stage biotechnology firm, focusing on developing and commercializing novel cell therapies targeting significant medical conditions. It generates revenue primarily through collaborations, clinical trials, and potential future product sales in areas such as ophthalmology, neurology, and oncology.

Additional Information

Lineage Cell Therapeutics is currently advancing several therapies through various stages of clinical trials, including OpRegen for dry age-related macular degeneration, and OPC1 targeting cervical spinal cord injuries. The company is engaged in ongoing research and has established partnerships to enhance its development capabilities, positioning itself as a key player in regenerative medicine.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

68

CEO

Mr. Brian M. Culley M.A., M.B.A.

Country

United States

IPO Year

1992

Lineage Cell Therapeutics Inc (LCTX) Latest News & Analysis

LCTX stock latest news image
Quick Summary

Lineage Cell Therapeutics (LCTX) has launched the DOSED clinical study to assess the safety and efficacy of a new device for delivering oligodendrocyte progenitor cells in spinal cord injury treatments.

Why It Matters

The initiation of the DOSED clinical study by Lineage Cell Therapeutics could signal advancements in spinal cord injury treatments, potentially impacting stock performance and investor sentiment in biotech.

Source: Business Wire
Market Sentiment: Neutral
LCTX stock latest news image
Quick Summary

Lineage Cell Therapeutics (LCTX) CEO Brian M. Culley will present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025, at 12:40 PM ET. The event is virtual.

Why It Matters

Brian M. Culley's presentation at a major healthcare conference highlights Lineage Cell Therapeutics' focus on innovative therapies, which could attract investor interest and impact stock performance.

Source: Business Wire
Market Sentiment: Neutral
LCTX stock latest news image
Quick Summary

Insider purchases have decreased since the start of the year, indicating lower activity among company executives buying their own stock.

Why It Matters

Lower insider purchases may signal reduced confidence in company performance, potentially leading to decreased stock prices and increased volatility.

Source: 24/7 Wall Street
Market Sentiment: Positive
LCTX stock latest news image
Quick Summary

Lineage Cell (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increasing optimism about its earnings prospects.

Why It Matters

Lineage Cell's upgrade to a Zacks Rank #1 signals strong earnings potential, suggesting increased investor confidence and possible stock price appreciation.

Source: Zacks Investment Research
Market Sentiment: Positive
LCTX stock latest news image
Quick Summary

Lineage Cell Therapeutics (NYSE: LCTX) has closed the second tranche of a registered direct offering, raising an additional amount towards a total of $66 million, following a $24 million first tranche in November 2024.

Why It Matters

Lineage Cell Therapeutics secured an additional $42 million in funding, enhancing its financial position to advance clinical-stage cell therapies, which could impact future growth and stock performance.

Source: Business Wire
Market Sentiment: Neutral
LCTX stock latest news image
Quick Summary

Lineage Cell Therapeutics (NYSE: LCTX) shared a letter to shareholders outlining recent achievements and its outlook for 2025, focusing on its allogeneic cell therapy developments.

Why It Matters

Lineage Cell Therapeutics' shareholder letter indicates progress in clinical development and outlines future plans, potentially impacting stock performance and investor sentiment.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About LCTX Stock

What is Lineage Cell Therapeutics Inc's (LCTX) stock forecast for 2025?

Based on our analysis of 8 Wall Street analysts, Lineage Cell Therapeutics Inc (LCTX) has a median price target of $4.00. The highest price target is $9.00 and the lowest is $2.00.

Is LCTX stock a good investment in 2025?

According to current analyst ratings, LCTX has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.69. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for LCTX stock?

Wall Street analysts predict LCTX stock could reach $4.00 in the next 12 months. This represents a 479.7% increase from the current price of $0.69. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Lineage Cell Therapeutics Inc's business model?

The company operates as a clinical-stage biotechnology firm, focusing on developing and commercializing novel cell therapies targeting significant medical conditions. It generates revenue primarily through collaborations, clinical trials, and potential future product sales in areas such as ophthalmology, neurology, and oncology.

What is the highest forecasted price for LCTX Lineage Cell Therapeutics Inc?

The highest price target for LCTX is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,204.3% increase from the current price of $0.69.

What is the lowest forecasted price for LCTX Lineage Cell Therapeutics Inc?

The lowest price target for LCTX is $2.00 from Jason Kolbert at D. Boral Capital, which represents a 189.9% increase from the current price of $0.69.

What is the overall LCTX consensus from analysts for Lineage Cell Therapeutics Inc?

The overall analyst consensus for LCTX is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.00.

How accurate are LCTX stock price projections?

Stock price projections, including those for Lineage Cell Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.